Streamline The Critical Path For Gene Therapy: Key Considerations For The AAV Analytical Lifecycle

Advances in adeno-associated virus (AAV) vectors have significantly enhanced gene therapy with improved target specificity, potency, and production efficiency. However, analytical activities often become a critical bottleneck in the development timeline.

This webinar provides essential considerations for phase-appropriate AAV characterization and release activities, spanning from pre-clinical to late-phase products. Discover how to streamline your journey to the clinic by strategically managing your analytics.

We specifically discuss potential challenges in validating late-stage analytics for Process Performance Qualification (PPQ) and commercial release and effective strategies for maturing both platform and product-specific assays.